Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H19O10P.2Na |
Molecular Weight | 496.3122 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].COC1=CC(=CC(OC)=C1OC)C(=O)C2=C(C)OC3=C2C=CC(OC)=C3OP([O-])([O-])=O
InChI
InChIKey=VVIPLWCZZYERCA-UHFFFAOYSA-L
InChI=1S/C20H21O10P.2Na/c1-10-16(17(21)11-8-14(26-3)19(28-5)15(9-11)27-4)12-6-7-13(25-2)20(18(12)29-10)30-31(22,23)24;;/h6-9H,1-5H3,(H2,22,23,24);;/q;2*+1/p-2
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C20H19O10P |
Molecular Weight | 450.3326 |
Charge | -2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
BNC105P, a vascular disrupting agent, is a disodium phosphate ester prodrug of BNC105. BNC105P is a tubulin polymerization inhibitor that suppresses cancer cell proliferation. BNC105P participated in phase I/II trial for patients with metastatic renal cell carcinoma. Although the primary endpoint was not met in an unselected population, correlative studies suggested several biomarkers that warrant further prospective evaluation. Besides, BNC105P was involved in phase II clinical trial as second-line chemotherapy for advanced malignant pleural mesothelioma. The drug was safe and tolerable, but the sole response was insufficient to warrant further research as a single agent. In addition, BNC105P in combination with Ibrutinib was studied in phase I trials for patients with chronic lymphocytic leukemia to determine the preliminary assessment of the efficacy.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25788492
Metastatic Renal Cell Carcinoma: In the phase I study (N = 15), a dose of BNC105P at 16 mg/m(2) with everolimus at 10 mg daily was identified as the recommended phase II dose.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:52:06 GMT 2023
by
admin
on
Fri Dec 15 19:52:06 GMT 2023
|
Record UNII |
E3052198GM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C88338
Created by
admin on Fri Dec 15 19:52:06 GMT 2023 , Edited by admin on Fri Dec 15 19:52:06 GMT 2023
|
PRIMARY | |||
|
945771-96-0
Created by
admin on Fri Dec 15 19:52:06 GMT 2023 , Edited by admin on Fri Dec 15 19:52:06 GMT 2023
|
PRIMARY | |||
|
16678086
Created by
admin on Fri Dec 15 19:52:06 GMT 2023 , Edited by admin on Fri Dec 15 19:52:06 GMT 2023
|
PRIMARY | |||
|
E3052198GM
Created by
admin on Fri Dec 15 19:52:06 GMT 2023 , Edited by admin on Fri Dec 15 19:52:06 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |